The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck had earlier on Monday said the CDC's Advisory Committee on Immunization Practices was expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.